Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

156
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
156
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

104
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
104
Censoring Survival Data01:09

Censoring Survival Data

69
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
69
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

188
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
188
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

101
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
101
Multiple Comparison Tests01:13

Multiple Comparison Tests

3.9K
Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing surrogate heterogeneity in real world data using meta-learners.

Journal of causal inference·2026
Same author

An Open-Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Model-Free Approach to Evaluate a Censored Intermediate Outcome as a Surrogate for Overall Survival.

Statistics in medicine·2025
Same author

RISE: Two-Stage Rank-Based Identification of High-Dimensional Surrogate Markers Applied to Vaccinology.

Statistics in medicine·2025
Same author

Semiparametric joint modeling to estimate the treatment effect on a longitudinal surrogate with application to chronic kidney disease trials.

Biometrics·2025
Same author

Robust evaluation of longitudinal surrogate markers with censored data.

Journal of the Royal Statistical Society. Series B, Statistical methodology·2025
Same journal

Statistical analysis of disease onset during lifespan with left truncation.

Biometrics·2026
Same journal

Interim analysis in sequential multiple assignment randomized trials for survival outcomes.

Biometrics·2026
Same journal

Acknowledgment of Referees 2025.

Biometrics·2026
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Group sequential testing of a treatment effect using a surrogate marker.

Layla Parast1, Jay Bartroff1

  • 1Department of Statistics and Data Sciences, The University of Texas at Austin, Austin, TX 78712, United States.

Biometrics
|October 8, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces novel group sequential methods for analyzing treatment effects using repeatedly measured surrogate markers. These methods enable earlier decisions in clinical trials by allowing early stopping for efficacy or futility.

Keywords:
clinical trialfutility stoppinggroup sequential testingstopping boundariessurrogate marker

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:27

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

686
The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan
11:58

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan

Published on: June 29, 2018

9.4K

Related Experiment Videos

Last Updated: Jun 11, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:27

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

686
The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan
11:58

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan

Published on: June 29, 2018

9.4K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmaceutical Research

Background:

  • Surrogate markers can expedite treatment effect evaluation, but methods for their use in future studies are limited.
  • Existing approaches often rely on parametric assumptions or single time-point surrogate data.
  • There's a need for flexible methods to test treatment effects using longitudinal surrogate marker data.

Purpose of the Study:

  • To develop group sequential procedures for treatment effect testing using repeatedly measured surrogate markers.
  • To enable early stopping for efficacy or futility in clinical trials based on surrogate marker data.
  • To extend existing nonparametric single time-point surrogate marker tests to a longitudinal setting.

Main Methods:

  • Utilized a previously proposed nonparametric test for treatment effects based on surrogate marker information.
  • Developed group sequential procedures incorporating correlated surrogate-based nonparametric test statistics at multiple time points.
  • Derived properties of the test statistics and computed stopping boundaries for early trial termination.

Main Results:

  • The proposed group sequential procedures allow for early stopping for significant treatment effects or futility.
  • The performance of the new methods was evaluated through simulation studies.
  • The methodology was illustrated using data from two AIDS clinical trials.

Conclusions:

  • Group sequential methods can be effectively applied to longitudinal surrogate marker data for treatment effect testing.
  • These methods offer a flexible, nonparametric alternative to existing approaches, enhancing clinical trial efficiency.
  • The developed procedures facilitate earlier and more informed decision-making in clinical research.